undamentalytics Newsletter
Sign in

Neurocrine Biosciences Inc income statement

In fiscal 2025, Neurocrine Biosciences Inc reported revenue of $2.86bn, up 21.4% on the year before, operating income of $619m (a 21.6% margin) and net income of $479m, or $4.67 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue33477533020151624517881,0461,1341,4891,8872,3552,8613,702
Cost of revenue———————015—101423403452—
Gross profit———————15160446—1,0361,1191,4661,8472,3212,808—
Research and development3431313739468194122161—2753284645657311,0161,233
Selling, general and administrative——————32681702493544335837538881,0071,1561,426
General and administrative141312131318————————————
Operating income−54−14341−50−64−94−147−1313772163103249251571619887
Interest expense——————00203132332675———
Income before tax———————−141−1432247107101214332486705932
Income tax——0000000110−301125982145227230
Net income−51−8385−46−61−89−141−143213740790155250341479703
Diluted EPS−$1.30−$0.15$0.67$0.08−$0.69−$0.81−$1.05−$1.63−$1.62$0.22$0.39$4.16$0.92$1.56$2.47$3.29$4.67$6.74
Diluted shares (average)39m53m56m67m67m75m84m87m88m95m96m98m98m99m101m104m103m104m
EBITDA−50−12352−49−64−93−146−1294180172113264269594645918

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BMRN vs NBIXARGX vs NBIXBNTX vs NBIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Neurocrine Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neurocrine Biosciences Inc.